Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliations: Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California (Dr Engel; firstname.lastname@example.org); and University of Rochester, Rochester, New York (Drs McDermott and Langfitt).
In Reply: We appreciate the concern of Dr Kieling and colleagues regarding the small number of participants in ERSET. Our original plan was to make HRQOL the primary outcome measure, but we changed this to seizure freedom at the request of the National Institutes of Health review panel prior to approval for funding. Nevertheless, we believe our data support a benefit of surgery on HRQOL. Although the effect at 24 months did not reach statistical significance based on the primary intention-to-treat analysis (P = .08), significant differences were found at all earlier time points (P < .009) and at 24 months when postsurgery data from participants in the medical group who received surgery were excluded. The observed effects on secondary outcomes such as driving and socialization further justify a conclusion that early surgery results in psychosocial benefits relative to continued medical management.
Engel J, McDermott MP, Langfitt JT. Treatment of Refractory Mesial Temporal Lobe Epilepsy—Reply. JAMA. 2012;307(23):2483–2485. doi:10.1001/jama.2012.4991
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: